Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and r...
Saved in:
| Published in: | The Lancet infectious diseases Vol. 16; no. 5; pp. 565 - 575 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Ltd
01.05.2016
Elsevier Limited New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001 Elsevier Science ;, The Lancet Pub. Group |
| Subjects: | |
| ISSN: | 1473-3099, 1474-4457 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.
The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene.
We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20–1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]).
We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial.
The Wellcome Trust. |
|---|---|
| AbstractList | Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.
The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene.
We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20–1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]).
We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial.
The Wellcome Trust. Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1.50, 95% CI 1.27-1.77 for CD4 cell count <100 cells per mu L). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1.48, 95% CI 1.20-1.82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145700 copies per mL [SE 12480] versus 133900 copies per mL [SE 16650; p=0.626]). Interpretation We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial. Funding The Wellcome Trust. Summary Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase ( RT ) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27–1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20–1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]). Interpretation We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial. Funding The Wellcome Trust. BACKGROUNDAntiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.METHODSThe TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene.FINDINGSWe included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27-1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20-1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]).INTERPRETATIONWe recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial.FUNDINGThe Wellcome Trust. Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with fi rst-line tenofovir-containing ART. MethodsThe TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a fi rst-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defi ned as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. FindingsWe included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1•50, 95% CI 1•27-1•77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1•48, 95% CI 1•20-1•82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0•626]). Interpretation We recorded drug resistance in a high proportion of patients after virological failure on a tenofovircontaining fi rst-line regimen across low-income and middle-income regions. Eff ective surveillance for transmission of drug resistance is crucial. Funding The Wellcome Trust. Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART. Methods The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to identify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defined as presence of K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene. Findings We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of tenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate most strongly associated with the development of tenofovir resistance (odds ratio [OR] 1·50, 95% CI 1·27-1·77 for CD4 cell count <100 cells per μL). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance across regions (OR 1·48, 95% CI 1·20-1·82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine analogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean plasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies per mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0·626]). Interpretation We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir-containing first-line regimen across low-income and middle-income regions. Effective surveillance for transmission of drug resistance is crucial. Funding The Wellcome Trust. |
| Author | Schmidt, Daniel Perno, Carlo F Schulter, Eugene Smit, Erasmus Helvas, Elias K Juma, James M De Oliveira, Tulio Ndembi, Nicaise Hamers, Raph L Clumeck, Nathan Pillay, Deenan Kantor, Rami Mukui, Irene Brooks, Katherine A Sabin, Caroline Reyes-Terán, Gustavo Kumarasamy, Nagalingeshwaran Dunn, David Kaleebu, Pontiano Gras, Luuk Sonnerborg, Anders Fessel, William J Hoffmann, Christopher J Charpentier, Charlotte Kerschberger, Bernard Murakami-Ogasawara, Akio Sirivichayakul, Sunee Shafer, Robert W Avila-Rios, Santiago Gupta, Ravindra K Blanco, Jose L Mekprasan, Suwanna Agolory, Simon Antinori, Antonio Tang, Michele Rinke de Wit, Tobias Romero, Karla Mussini, Cristina Sunpath, Henry Yang, Chunfu Günthard, Huldrych F Asio, Juliet Monge, Susana Goedhals, Dominique Morris, Lynn Kanki, Phyllis J Tostevin, Anna Camacho, Ricardo Aghokeng, Avelin Raizes, Elliot Watera, Christine Bester, Philip A Latini, Alessandra Van Vuuren, Cloete Marconi, Vincent C Diero, Lameck Andreoni, Massimo Santoro, MARIA M Todesco, Eva Neogi, Ujjwal Ruxrungtham, Kiat Gregson, John Mor |
| Author_xml | – sequence: 1 givenname: John surname: Gregson fullname: Gregson, John – sequence: 2 givenname: Michele surname: Tang fullname: Tang, Michele – sequence: 3 givenname: Nicaise surname: Ndembi fullname: Ndembi, Nicaise – sequence: 4 givenname: Raph L surname: Hamers fullname: Hamers, Raph L – sequence: 5 givenname: Soo-Yon surname: Rhee fullname: Rhee, Soo-Yon – sequence: 6 givenname: Vincent C surname: Marconi fullname: Marconi, Vincent C – sequence: 7 givenname: Lameck surname: Diero fullname: Diero, Lameck – sequence: 8 givenname: Katherine A surname: Brooks fullname: Brooks, Katherine A – sequence: 9 givenname: Kristof surname: Theys fullname: Theys, Kristof – sequence: 10 givenname: Tobias surname: Rinke de Wit fullname: Rinke de Wit, Tobias – sequence: 11 givenname: Monica surname: Arruda fullname: Arruda, Monica – sequence: 12 givenname: Frederico surname: Garcia fullname: Garcia, Frederico – sequence: 13 givenname: Susana surname: Monge fullname: Monge, Susana – sequence: 14 givenname: Huldrych F surname: Günthard fullname: Günthard, Huldrych F – sequence: 15 givenname: Christopher J surname: Hoffmann fullname: Hoffmann, Christopher J – sequence: 16 givenname: Phyllis J surname: Kanki fullname: Kanki, Phyllis J – sequence: 17 givenname: Nagalingeshwaran surname: Kumarasamy fullname: Kumarasamy, Nagalingeshwaran – sequence: 18 givenname: Bernard surname: Kerschberger fullname: Kerschberger, Bernard – sequence: 19 givenname: Orna surname: Mor fullname: Mor, Orna – sequence: 20 givenname: Charlotte surname: Charpentier fullname: Charpentier, Charlotte – sequence: 21 givenname: Eva surname: Todesco fullname: Todesco, Eva – sequence: 22 givenname: Casper surname: Rokx fullname: Rokx, Casper – sequence: 23 givenname: Luuk surname: Gras fullname: Gras, Luuk – sequence: 24 givenname: Elias K surname: Helvas fullname: Helvas, Elias K – sequence: 25 givenname: Henry surname: Sunpath fullname: Sunpath, Henry – sequence: 26 givenname: Domenico surname: Di Carlo fullname: Di Carlo, Domenico – sequence: 27 givenname: Antonio surname: Antinori fullname: Antinori, Antonio – sequence: 28 givenname: Massimo surname: Andreoni fullname: Andreoni, Massimo – sequence: 29 givenname: Alessandra surname: Latini fullname: Latini, Alessandra – sequence: 30 givenname: Cristina surname: Mussini fullname: Mussini, Cristina – sequence: 31 givenname: Avelin surname: Aghokeng fullname: Aghokeng, Avelin – sequence: 32 givenname: Anders surname: Sonnerborg fullname: Sonnerborg, Anders – sequence: 33 givenname: Ujjwal surname: Neogi fullname: Neogi, Ujjwal – sequence: 34 givenname: William J surname: Fessel fullname: Fessel, William J – sequence: 35 givenname: Simon surname: Agolory fullname: Agolory, Simon – sequence: 36 givenname: Chunfu surname: Yang fullname: Yang, Chunfu – sequence: 37 givenname: Jose L surname: Blanco fullname: Blanco, Jose L – sequence: 38 givenname: James M surname: Juma fullname: Juma, James M – sequence: 39 givenname: Erasmus surname: Smit fullname: Smit, Erasmus – sequence: 40 givenname: Daniel surname: Schmidt fullname: Schmidt, Daniel – sequence: 41 givenname: Christine surname: Watera fullname: Watera, Christine – sequence: 42 givenname: Juliet surname: Asio fullname: Asio, Juliet – sequence: 43 givenname: Wilford surname: Kurungi fullname: Kurungi, Wilford – sequence: 44 givenname: Anna surname: Tostevin fullname: Tostevin, Anna – sequence: 45 givenname: Tal surname: El-Hay fullname: El-Hay, Tal – sequence: 46 givenname: Nathan surname: Clumeck fullname: Clumeck, Nathan – sequence: 47 givenname: Dominique surname: Goedhals fullname: Goedhals, Dominique – sequence: 48 givenname: Cloete surname: Van Vuuren fullname: Van Vuuren, Cloete – sequence: 49 givenname: Philip A surname: Bester fullname: Bester, Philip A – sequence: 50 givenname: Caroline surname: Sabin fullname: Sabin, Caroline – sequence: 51 givenname: Irene surname: Mukui fullname: Mukui, Irene – sequence: 52 givenname: MARIA M surname: Santoro fullname: Santoro, MARIA M – sequence: 53 givenname: Carlo F surname: Perno fullname: Perno, Carlo F – sequence: 54 givenname: Gillian surname: Hunt fullname: Hunt, Gillian – sequence: 55 givenname: Lynn surname: Morris fullname: Morris, Lynn – sequence: 56 givenname: Ricardo surname: Camacho fullname: Camacho, Ricardo – sequence: 57 givenname: Tulio surname: De Oliveira fullname: De Oliveira, Tulio – sequence: 58 givenname: Deenan surname: Pillay fullname: Pillay, Deenan – sequence: 59 givenname: Eugene surname: Schulter fullname: Schulter, Eugene – sequence: 60 givenname: Akio surname: Murakami-Ogasawara fullname: Murakami-Ogasawara, Akio – sequence: 61 givenname: Gustavo surname: Reyes-Terán fullname: Reyes-Terán, Gustavo – sequence: 62 givenname: Karla surname: Romero fullname: Romero, Karla – sequence: 63 givenname: Santiago surname: Avila-Rios fullname: Avila-Rios, Santiago – sequence: 64 givenname: Sunee surname: Sirivichayakul fullname: Sirivichayakul, Sunee – sequence: 65 givenname: Kiat surname: Ruxrungtham fullname: Ruxrungtham, Kiat – sequence: 66 givenname: Suwanna surname: Mekprasan fullname: Mekprasan, Suwanna – sequence: 67 givenname: David surname: Dunn fullname: Dunn, David – sequence: 68 givenname: Pontiano surname: Kaleebu fullname: Kaleebu, Pontiano – sequence: 69 givenname: Elliot surname: Raizes fullname: Raizes, Elliot – sequence: 70 givenname: Rami surname: Kantor fullname: Kantor, Rami – sequence: 71 givenname: Robert W surname: Shafer fullname: Shafer, Robert W – sequence: 72 givenname: Ravindra K surname: Gupta fullname: Gupta, Ravindra K |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26831472$$D View this record in MEDLINE/PubMed https://hal.science/hal-04985809$$DView record in HAL http://kipublications.ki.se/Default.aspx?queryparsed=id:133372469$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNqNUttu1DAUjFARvcAngCzx0j4E7MSOHRBFVQXdSpX6wO3R8tonW7dJvNjOov0afhVn0wJdCZUnW3Nm5pxjz36207sesuw5wa8IJtXrT4TyMi9xXR8SdoQxK6tcPMr2EkxzShnf2dwnym62H8I1xoQTTJ9ku0UlylQs9rKfZ62bqxbB0hrorGvdYo1cg4wfFshDsCGqXgNSTQSPGmXbwcNI-Da7THXtug56AwY11oeYt7aHBC9sQgNqnEfKDG1Es_OvOUG2b0BH6_o3SKEu4VZDH_2oiN6F5VhcAdLuyvmIQhzM-mn2uFFtgGe350H25eOHz6ez_OLy7Pz05CLXnLOYC1YY2hjOFCGUcl0JphUxhNV0XtOGNwUUuIBKAYDGDacVN2VDDJ_X3DCCy4Msn3zDD1gOc7n0tlN-LZ2y8ha6STeQDHPGReIfT_xU6cBs9lDtPdn9Sm-v5MKtJBUlY6JMBkeTwdWWbHZyIUcM01owgesVSdzD22befR8gRNnZoKFtVQ9uCJIIwgUVdSUepvKa0prVgifqyy3qtRt8n15Zjna0EjUe53zx96K_R72LUCK8nQg6fWHw0Ehtoxp_Oe1tW0mwHAMrN4GVYxolYXITWDnOy7bUdw0e0r2fdJBCsbLgZdAWUlKNTamM0jj7oMPxloNO6bVatTewhvDnLWQoJJ5MRg_CNg6jwbt_G_zHAL8AKEUtAQ |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1111_hiv_13298 crossref_primary_10_1016_j_ijantimicag_2024_107294 crossref_primary_10_1590_s1678_9946202466035 crossref_primary_10_1093_cid_cix015 crossref_primary_10_1177_1179559X17715241 crossref_primary_10_1371_journal_pone_0192357 crossref_primary_10_1016_S1473_3099_17_30702_8 crossref_primary_10_1016_S2352_3018_18_30331_X crossref_primary_10_1093_jac_dkw583 crossref_primary_10_1097_MD_0000000000027460 crossref_primary_10_1016_S2352_3018_18_30173_5 crossref_primary_10_22207_JPAM_18_4_18 crossref_primary_10_1093_jac_dkaa287 crossref_primary_10_1097_QAD_0000000000002623 crossref_primary_10_1097_QAI_0000000000001717 crossref_primary_10_1371_journal_pone_0195744 crossref_primary_10_2217_fvl_2018_0084 crossref_primary_10_1111_hiv_12877 crossref_primary_10_1089_aid_2017_0112 crossref_primary_10_1097_QAD_0000000000001494 crossref_primary_10_1016_S2352_3018_19_30146_8 crossref_primary_10_1038_s41586_019_1027_4 crossref_primary_10_3390_v16071163 crossref_primary_10_1093_jac_dkae084 crossref_primary_10_1093_jac_dkw218 crossref_primary_10_1128_JCM_01045_20 crossref_primary_10_3389_fimmu_2021_702172 crossref_primary_10_1371_journal_pone_0308869 crossref_primary_10_1177_20499361221077544 crossref_primary_10_1093_cid_ciz209 crossref_primary_10_1186_s13063_019_3545_7 crossref_primary_10_1093_femspd_ftx078 crossref_primary_10_1093_cid_ciab1006 crossref_primary_10_1097_QAI_0000000000001943 crossref_primary_10_1186_s12981_020_00317_9 crossref_primary_10_1007_s10461_020_02969_0 crossref_primary_10_1007_s40265_025_02181_1 crossref_primary_10_1016_S1473_3099_17_30631_X crossref_primary_10_12688_f1000research_121980_1 crossref_primary_10_2174_011570162X344689250331081024 crossref_primary_10_1016_j_ijmmb_2023_100520 crossref_primary_10_1002_jmv_25245 crossref_primary_10_1093_jac_dkab002 crossref_primary_10_1097_QAD_0000000000002358 crossref_primary_10_4102_sajhivmed_v20i1_847 crossref_primary_10_1186_s12977_016_0304_7 crossref_primary_10_1097_QAD_0000000000002234 crossref_primary_10_1093_infdis_jiae260 crossref_primary_10_1093_jac_dkaa033 crossref_primary_10_1186_s12981_021_00352_0 crossref_primary_10_1016_S2352_3018_20_30252_6 crossref_primary_10_1016_S2352_3018_17_30069_3 crossref_primary_10_1186_s12879_021_06757_6 crossref_primary_10_1186_s40249_019_0573_1 crossref_primary_10_1089_aid_2021_0181 crossref_primary_10_3390_v12070729 crossref_primary_10_1097_MD_0000000000004886 crossref_primary_10_3390_v17020206 crossref_primary_10_1016_j_vaccine_2017_12_004 crossref_primary_10_1093_jac_dkx252 crossref_primary_10_1093_infdis_jiz667 crossref_primary_10_1186_s12887_019_1402_1 crossref_primary_10_2147_IDR_S337485 crossref_primary_10_1097_CM9_0000000000003317 crossref_primary_10_1177_1363459316649763 crossref_primary_10_30699_ijmm_14_6_512 crossref_primary_10_1089_aid_2022_0155 crossref_primary_10_1186_s12889_020_8406_5 crossref_primary_10_3390_molecules25061338 crossref_primary_10_1111_trf_14195 crossref_primary_10_1093_cid_cix430 crossref_primary_10_1016_j_actatropica_2017_12_021 crossref_primary_10_1016_S2352_3018_18_30093_6 crossref_primary_10_1097_QAI_0000000000003157 crossref_primary_10_1016_j_ijregi_2025_100645 crossref_primary_10_1186_s12981_020_0261_z crossref_primary_10_1038_s41598_019_47917_8 crossref_primary_10_1371_journal_pone_0281528 crossref_primary_10_1089_aid_2019_0279 crossref_primary_10_1016_j_csbj_2020_12_022 crossref_primary_10_3390_v13030451 crossref_primary_10_1097_QAI_0000000000003385 crossref_primary_10_1080_14756366_2020_1835884 crossref_primary_10_1186_s12879_024_09156_9 crossref_primary_10_1016_S2352_3018_22_00136_9 crossref_primary_10_1093_jac_dkaa537 crossref_primary_10_1038_s41573_024_00933_4 crossref_primary_10_20935_AcadMed7889 crossref_primary_10_7759_cureus_68530 crossref_primary_10_1093_jac_dkx091 crossref_primary_10_1038_srep38153 crossref_primary_10_1093_jac_dkz272 crossref_primary_10_2174_0118746136382073250806110823 crossref_primary_10_1089_aid_2019_0151 crossref_primary_10_1016_j_meegid_2017_07_003 crossref_primary_10_1186_s40360_019_0307_9 crossref_primary_10_3390_ijms22105304 crossref_primary_10_1016_S1473_3099_16_30118_9 crossref_primary_10_1093_infdis_jiaa417 crossref_primary_10_1089_aid_2016_0301 crossref_primary_10_1371_journal_pone_0206409 crossref_primary_10_1016_j_virol_2022_08_011 crossref_primary_10_1177_2325958218759211 crossref_primary_10_1089_aid_2020_0272 crossref_primary_10_1186_s12879_020_4808_3 crossref_primary_10_1093_infdis_jiw213 crossref_primary_10_1016_S1473_3099_16_30137_2 crossref_primary_10_1021_acsmedchemlett_4c00268 crossref_primary_10_1080_09540121_2023_2175771 crossref_primary_10_1097_QAD_0000000000002936 crossref_primary_10_1016_S1473_3099_16_30469_8 crossref_primary_10_1093_jac_dkz261 crossref_primary_10_1093_jac_dkz264 crossref_primary_10_2217_fvl_2018_0208 crossref_primary_10_1093_ofid_ofx219 crossref_primary_10_1097_QAI_0000000000001479 crossref_primary_10_1186_s12879_022_07894_2 crossref_primary_10_1093_jac_dkad195 crossref_primary_10_1016_j_ijid_2021_03_018 crossref_primary_10_1038_s41467_024_47254_z crossref_primary_10_1097_QAD_0000000000003082 crossref_primary_10_1186_s12879_022_07453_9 crossref_primary_10_1016_j_micpath_2020_104221 crossref_primary_10_1016_j_ijid_2022_11_012 crossref_primary_10_1093_ve_vex008 crossref_primary_10_1038_s41467_023_42550_6 crossref_primary_10_1016_j_jhep_2019_02_006 crossref_primary_10_1093_infdis_jix432 crossref_primary_10_1371_journal_pone_0218649 crossref_primary_10_1097_ID9_0000000000000169 crossref_primary_10_1371_journal_pone_0232649 crossref_primary_10_1093_ofid_ofab559 crossref_primary_10_1093_jac_dkz005 crossref_primary_10_1089_aid_2018_0202 crossref_primary_10_1016_j_jcv_2019_06_003 crossref_primary_10_1016_S1473_3099_18_30647_9 crossref_primary_10_1136_bmjopen_2024_085819 crossref_primary_10_1111_tmi_13373 crossref_primary_10_1016_j_jclinepi_2022_02_005 crossref_primary_10_1093_cid_ciw130 crossref_primary_10_1093_infdis_jiw214 crossref_primary_10_1080_21505594_2023_2171632 crossref_primary_10_1097_QAD_0000000000001586 crossref_primary_10_1186_s12981_017_0161_z crossref_primary_10_1097_QAD_0000000000003244 crossref_primary_10_3390_ph12020062 crossref_primary_10_1016_j_chom_2019_06_010 crossref_primary_10_1093_jac_dky428 crossref_primary_10_1371_journal_pone_0186619 crossref_primary_10_4103_cmrp_cmrp_98_23 crossref_primary_10_1016_S1473_3099_17_30709_0 crossref_primary_10_1080_14756366_2021_1887170 crossref_primary_10_12688_wellcomeopenres_16597_1 crossref_primary_10_1016_S1473_3099_16_30447_9 crossref_primary_10_1093_cid_ciz372 crossref_primary_10_3390_v14091898 crossref_primary_10_1186_s12879_021_06952_5 crossref_primary_10_1371_journal_pone_0234937 crossref_primary_10_1016_j_coviro_2017_12_001 crossref_primary_10_1016_j_jcv_2019_05_012 crossref_primary_10_1186_s12985_020_01311_3 crossref_primary_10_1016_j_ebiom_2017_03_024 crossref_primary_10_1371_journal_pone_0271910 crossref_primary_10_1128_JVI_01841_16 crossref_primary_10_1016_j_antiviral_2018_02_010 crossref_primary_10_1097_QAI_0000000000001285 crossref_primary_10_1002_jia2_25849 crossref_primary_10_1080_17512433_2020_1782737 crossref_primary_10_1016_S1473_3099_18_30710_2 crossref_primary_10_1093_jac_dkz067 crossref_primary_10_1371_journal_pone_0234133 crossref_primary_10_1016_S2352_3018_22_00327_7 crossref_primary_10_1093_infdis_jiz631 crossref_primary_10_1093_jac_dky256 crossref_primary_10_4103_NJPT_NJPT_35_23 crossref_primary_10_1186_s12879_018_3400_6 crossref_primary_10_1177_0956462417724707 crossref_primary_10_1016_S2352_3018_20_30172_7 crossref_primary_10_1093_infdis_jix605 crossref_primary_10_1371_journal_pone_0224292 crossref_primary_10_1093_ofid_ofx125 crossref_primary_10_1093_jac_dkab385 crossref_primary_10_1371_journal_pone_0206406 crossref_primary_10_1038_s41467_020_19801_x crossref_primary_10_1128_JVI_01580_20 |
| Cites_doi | 10.1056/NEJMoa0906768 10.1371/journal.pone.0079981 10.3390/v6104080 10.1097/COH.0b013e32835b809d 10.1086/429411 10.1093/jac/dkv183 10.1001/jama.296.6.679 10.1111/j.1468-1293.2006.00404.x 10.1093/infdis/jis613 10.1086/605894 10.1093/cid/civ556 10.3390/v7072790 10.1093/cid/cir1034 10.1056/NEJM200003303421303 10.1086/648444 10.1093/cid/cis207 10.1097/QAI.0b013e3181b05f7c 10.1016/S1473-3099(14)70896-5 10.1128/JCM.43.3.1395-1400.2005 10.1097/QAD.0b013e328356886d 10.1097/QAD.0b013e32835b0f59 10.1016/j.jinf.2013.09.005 10.7448/IAS.15.2.17701 10.1086/651618 10.1016/S0140-6736(12)61038-1 10.1016/S0140-6736(08)61697-9 10.1016/S1473-3099(09)70136-7 10.1093/infdis/jis731 10.1093/cid/ciu763 |
| ContentType | Journal Article |
| Contributor | Schmidt, Daniel Perno, Carlo F Schulter, Eugene Smit, Erasmus Helvas, Elias K Juma, James M De Oliveira, Tulio Ndembi, Nicaise Hamers, Raph L Clumeck, Nathan Pillay, Deenan Kantor, Rami Mukui, Irene Brooks, Katherine A Sabin, Caroline Reyes-Terán, Gustavo Kumarasamy, Nagalingeshwaran Dunn, David Kaleebu, Pontiano Santoro, Maria M Gras, Luuk Sonnerborg, Anders Fessel, William J Hoffmann, Christopher J Charpentier, Charlotte Kerschberger, Bernard Murakami-Ogasawara, Akio Sirivichayakul, Sunee Shafer, Robert W Avila-Rios, Santiago Gupta, Ravindra K Blanco, Jose L Mekprasan, Suwanna Agolory, Simon Antinori, Antonio Tang, Michele Rinke de Wit, Tobias Romero, Karla Mussini, Cristina Sunpath, Henry Yang, Chunfu Günthard, Huldrych F Asio, Juliet Monge, Susana Goedhals, Dominique Morris, Lynn Kanki, Phyllis J Tostevin, Anna Camacho, Ricardo Aghokeng, Avelin Raizes, Elliot Watera, Christine Bester, Philip A Latini, Alessandra Van Vuuren, Cloete Marconi, Vincent C Diero, Lameck Andreoni, Massimo Todesco, Eva Neogi, Ujjwal Ruxrungtham, Kiat Gregson, John Mor |
| Contributor_xml | – sequence: 1 givenname: John surname: Gregson fullname: Gregson, John – sequence: 2 givenname: Michele surname: Tang fullname: Tang, Michele – sequence: 3 givenname: Nicaise surname: Ndembi fullname: Ndembi, Nicaise – sequence: 4 givenname: Raph L surname: Hamers fullname: Hamers, Raph L – sequence: 5 givenname: Soo-Yon surname: Rhee fullname: Rhee, Soo-Yon – sequence: 6 givenname: Vincent C surname: Marconi fullname: Marconi, Vincent C – sequence: 7 givenname: Lameck surname: Diero fullname: Diero, Lameck – sequence: 8 givenname: Katherine A surname: Brooks fullname: Brooks, Katherine A – sequence: 9 givenname: Kristof surname: Theys fullname: Theys, Kristof – sequence: 10 givenname: Tobias surname: Rinke de Wit fullname: Rinke de Wit, Tobias – sequence: 11 givenname: Monica surname: Arruda fullname: Arruda, Monica – sequence: 12 givenname: Frederico surname: Garcia fullname: Garcia, Frederico – sequence: 13 givenname: Susana surname: Monge fullname: Monge, Susana – sequence: 14 givenname: Huldrych F surname: Günthard fullname: Günthard, Huldrych F – sequence: 15 givenname: Christopher J surname: Hoffmann fullname: Hoffmann, Christopher J – sequence: 16 givenname: Phyllis J surname: Kanki fullname: Kanki, Phyllis J – sequence: 17 givenname: Nagalingeshwaran surname: Kumarasamy fullname: Kumarasamy, Nagalingeshwaran – sequence: 18 givenname: Bernard surname: Kerschberger fullname: Kerschberger, Bernard – sequence: 19 givenname: Orna surname: Mor fullname: Mor, Orna – sequence: 20 givenname: Charlotte surname: Charpentier fullname: Charpentier, Charlotte – sequence: 21 givenname: Eva surname: Todesco fullname: Todesco, Eva – sequence: 22 givenname: Casper surname: Rokx fullname: Rokx, Casper – sequence: 23 givenname: Luuk surname: Gras fullname: Gras, Luuk – sequence: 24 givenname: Elias K surname: Helvas fullname: Helvas, Elias K – sequence: 25 givenname: Henry surname: Sunpath fullname: Sunpath, Henry – sequence: 26 givenname: Domenico surname: Di Carlo fullname: Di Carlo, Domenico – sequence: 27 givenname: Antonio surname: Antinori fullname: Antinori, Antonio – sequence: 28 givenname: Massimo surname: Andreoni fullname: Andreoni, Massimo – sequence: 29 givenname: Alessandra surname: Latini fullname: Latini, Alessandra – sequence: 30 givenname: Cristina surname: Mussini fullname: Mussini, Cristina – sequence: 31 givenname: Avelin surname: Aghokeng fullname: Aghokeng, Avelin – sequence: 32 givenname: Anders surname: Sonnerborg fullname: Sonnerborg, Anders – sequence: 33 givenname: Ujjwal surname: Neogi fullname: Neogi, Ujjwal – sequence: 34 givenname: William J surname: Fessel fullname: Fessel, William J – sequence: 35 givenname: Simon surname: Agolory fullname: Agolory, Simon – sequence: 36 givenname: Chunfu surname: Yang fullname: Yang, Chunfu – sequence: 37 givenname: Jose L surname: Blanco fullname: Blanco, Jose L – sequence: 38 givenname: James M surname: Juma fullname: Juma, James M – sequence: 39 givenname: Erasmus surname: Smit fullname: Smit, Erasmus – sequence: 40 givenname: Daniel surname: Schmidt fullname: Schmidt, Daniel – sequence: 41 givenname: Christine surname: Watera fullname: Watera, Christine – sequence: 42 givenname: Juliet surname: Asio fullname: Asio, Juliet – sequence: 43 givenname: Wilford surname: Kurungi fullname: Kurungi, Wilford – sequence: 44 givenname: Anna surname: Tostevin fullname: Tostevin, Anna – sequence: 45 givenname: Tal surname: El-Hay fullname: El-Hay, Tal – sequence: 46 givenname: Nathan surname: Clumeck fullname: Clumeck, Nathan – sequence: 47 givenname: Dominique surname: Goedhals fullname: Goedhals, Dominique – sequence: 48 givenname: Cloete surname: Van Vuuren fullname: Van Vuuren, Cloete – sequence: 49 givenname: Philip A surname: Bester fullname: Bester, Philip A – sequence: 50 givenname: Caroline surname: Sabin fullname: Sabin, Caroline – sequence: 51 givenname: Irene surname: Mukui fullname: Mukui, Irene – sequence: 52 givenname: Maria M surname: Santoro fullname: Santoro, Maria M – sequence: 53 givenname: Carlo F surname: Perno fullname: Perno, Carlo F – sequence: 54 givenname: Gillian surname: Hunt fullname: Hunt, Gillian – sequence: 55 givenname: Lynn surname: Morris fullname: Morris, Lynn – sequence: 56 givenname: Ricardo surname: Camacho fullname: Camacho, Ricardo – sequence: 57 givenname: Tulio surname: De Oliveira fullname: De Oliveira, Tulio – sequence: 58 givenname: Deenan surname: Pillay fullname: Pillay, Deenan – sequence: 59 givenname: Eugene surname: Schulter fullname: Schulter, Eugene – sequence: 60 givenname: Akio surname: Murakami-Ogasawara fullname: Murakami-Ogasawara, Akio – sequence: 61 givenname: Gustavo surname: Reyes-Terán fullname: Reyes-Terán, Gustavo – sequence: 62 givenname: Karla surname: Romero fullname: Romero, Karla – sequence: 63 givenname: Santiago surname: Avila-Rios fullname: Avila-Rios, Santiago – sequence: 64 givenname: Sunee surname: Sirivichayakul fullname: Sirivichayakul, Sunee – sequence: 65 givenname: Kiat surname: Ruxrungtham fullname: Ruxrungtham, Kiat – sequence: 66 givenname: Suwanna surname: Mekprasan fullname: Mekprasan, Suwanna – sequence: 67 givenname: David surname: Dunn fullname: Dunn, David – sequence: 68 givenname: Pontiano surname: Kaleebu fullname: Kaleebu, Pontiano – sequence: 69 givenname: Elliot surname: Raizes fullname: Raizes, Elliot – sequence: 70 givenname: Rami surname: Kantor fullname: Kantor, Rami – sequence: 71 givenname: Robert W surname: Shafer fullname: Shafer, Robert W – sequence: 72 givenname: Ravindra K surname: Gupta fullname: Gupta, Ravindra K |
| Copyright | 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY The TenoRes Study Group. Open Access article distributed under the terms of CC BY Copyright © 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited May 2016 Attribution 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY 2016 |
| Copyright_xml | – notice: 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY – notice: The TenoRes Study Group. Open Access article distributed under the terms of CC BY – notice: Copyright © 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited May 2016 – notice: Attribution – notice: 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY 2016 |
| CorporateAuthor | The TenoRes Study Group TenoRes Study Group |
| CorporateAuthor_xml | – name: The TenoRes Study Group – name: TenoRes Study Group |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AEUYN AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7U8 7X8 JXQ 1XC VOOES 5PM ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1016/S1473-3099(15)00536-8 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition TOXLINE MEDLINE - Academic Toxline Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) TOXLINE MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE TOXLINE ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-4457 |
| EndPage | 575 |
| ExternalDocumentID | oai_swepub_ki_se_507578 PMC4835583 oai:HAL:hal-04985809v1 4036092931 26831472 10_1016_S1473_3099_15_00536_8 S1473309915005368 1_s2_0_S1473309915005368 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | Africa South of the Sahara |
| GeographicLocations_xml | – name: Africa South of the Sahara |
| GrantInformation | The Wellcome Trust. |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI068581 – fundername: Medical Research Council grantid: MC_UU_12023/15 – fundername: Wellcome Trust – fundername: NIAID NIH HHS grantid: U01 AI069907 – fundername: NIAID NIH HHS grantid: UM1 AI069456 – fundername: NIAID NIH HHS grantid: R01 AI098558 – fundername: Medical Research Council grantid: MR/M004236/1 – fundername: Medical Research Council grantid: MC_UU_12023/23 – fundername: Medical Research Council grantid: MC_U950080938 – fundername: Medical Research Council grantid: G0600044 |
| GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R ~HD 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF 6I. AAFTH ABLVK ABYKQ AJBFU ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7U9 7XB 8FK C1K H94 K9. M7N PKEHL PQEST PQUKI 7U8 7X8 JXQ 1XC VOOES 5PM ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c775t-852d4fd75a11447c685ca1d1594b94f7f2e202e6aeeec0f7467d3f1d7b97d5103 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 189 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000374272900027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1473-3099 |
| IngestDate | Tue Nov 25 03:36:20 EST 2025 Tue Nov 04 02:01:16 EST 2025 Tue Oct 14 20:45:45 EDT 2025 Sun Nov 09 12:14:54 EST 2025 Sun Nov 09 09:06:40 EST 2025 Mon Oct 06 18:33:20 EDT 2025 Mon Jul 21 05:50:57 EDT 2025 Sat Nov 29 07:04:23 EST 2025 Tue Nov 18 22:09:32 EST 2025 Fri Feb 23 02:26:57 EST 2024 Tue Feb 25 19:56:54 EST 2025 Tue Oct 14 19:31:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 Copyright © 2016 The TenoRes Study Group. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. Attribution: http://creativecommons.org/licenses/by This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c775t-852d4fd75a11447c685ca1d1594b94f7f2e202e6aeeec0f7467d3f1d7b97d5103 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Members listed at the end of the report |
| ORCID | 0000-0002-1414-0237 |
| OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:133372469 |
| PMID | 26831472 |
| PQID | 1784468903 |
| PQPubID | 44001 |
| PageCount | 11 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_507578 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4835583 hal_primary_oai_HAL_hal_04985809v1 proquest_miscellaneous_1817848968 proquest_miscellaneous_1794495987 proquest_journals_1784468903 pubmed_primary_26831472 crossref_citationtrail_10_1016_S1473_3099_15_00536_8 crossref_primary_10_1016_S1473_3099_15_00536_8 elsevier_sciencedirect_doi_10_1016_S1473_3099_15_00536_8 elsevier_clinicalkeyesjournals_1_s2_0_S1473309915005368 elsevier_clinicalkey_doi_10_1016_S1473_3099_15_00536_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05-01 |
| PublicationDateYYYYMMDD | 2016-05-01 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | The Lancet infectious diseases |
| PublicationTitleAlternate | Lancet Infect Dis |
| PublicationYear | 2016 |
| Publisher | Elsevier Ltd Elsevier Limited New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001 Elsevier Science ;, The Lancet Pub. Group |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001 – name: Elsevier Science ;, The Lancet Pub. Group |
| References | Etiebet, Shepherd, Nowak (bib10) 2013; 27 Margot, Enejosa, Cheng, Miller, McColl (bib7) 2009; 52 Quinn, Wawer, Sewankambo (bib29) 2000; 342 Sax, Tierney, Collier (bib12) 2009; 361 Invernizzi, Coutsinos, Oliveira, Moisi, Brenner, Wainberg (bib32) 2009; 200 Gupta, Hill, Sawyer (bib16) 2009; 9 Chan, Huang, Kantor (bib30) 2012; 15 Apostolova, Funes, Blas-Garcia, Galindo, Alvarez, Esplugues (bib18) 2015; 70 O'Connor, Gardner, Mannheimer (bib21) 2013; 208 Margot, Lu, Cheng, Miller (bib6) 2006; 7 Hoffmann, Charalambous, Sim (bib14) 2009; 49 Gupta, Jordan, Sultan (bib17) 2012; 380 Ford, Meintjes, Pozniak (bib23) 2015; 15 Boender, Sigaloff, McMahon (bib31) 2015; 61 Wensing, Calvez, Gunthard (bib11) 2014; 22 Bennett, Jordan, Bertagnolio (bib19) 2012; 54 Garforth, Lwatula, Prasad (bib5) 2014; 6 Weber, Chakraborty, Weberova, Miller, Quiñones-Mateu (bib13) 2005; 43 Mills, Nachega, Buchan (bib20) 2006; 296 Granich, Gilks, Dye, De Cock, Williams (bib3) 2009; 373 Ford, Shubber, Hill (bib25) 2013; 8 Mackie, Phillips, Kaye, Booth, Geretti (bib15) 2010; 201 Mollan, Daar, Sax (bib22) 2012; 206 Tang, Kanki, Shafer (bib26) 2012; 54 Mesplède, Wainberg (bib27) 2015; 7 Hankins, Dybul (bib4) 2013; 8 (bib1) 2014 Sunpath, Wu, Gordon (bib9) 2012; 26 Wawer, Gray, Sewankambo (bib28) 2005; 191 bib2 Bulteel, Bansi-Matharu, Churchill (bib8) 2014; 68 Rokx, Fibriani, van de Vijver (bib24) 2015; 60 Ford (10.1016/S1473-3099(15)00536-8_bib25) 2013; 8 Gupta (10.1016/S1473-3099(15)00536-8_bib16) 2009; 9 Etiebet (10.1016/S1473-3099(15)00536-8_bib10) 2013; 27 Mackie (10.1016/S1473-3099(15)00536-8_bib15) 2010; 201 Ford (10.1016/S1473-3099(15)00536-8_bib23) 2015; 15 Wawer (10.1016/S1473-3099(15)00536-8_bib28) 2005; 191 Invernizzi (10.1016/S1473-3099(15)00536-8_bib32) 2009; 200 Hankins (10.1016/S1473-3099(15)00536-8_bib4) 2013; 8 Wensing (10.1016/S1473-3099(15)00536-8_bib11) 2014; 22 Mesplède (10.1016/S1473-3099(15)00536-8_bib27) 2015; 7 Boender (10.1016/S1473-3099(15)00536-8_bib31) 2015; 61 O'Connor (10.1016/S1473-3099(15)00536-8_bib21) 2013; 208 Mollan (10.1016/S1473-3099(15)00536-8_bib22) 2012; 206 Granich (10.1016/S1473-3099(15)00536-8_bib3) 2009; 373 Weber (10.1016/S1473-3099(15)00536-8_bib13) 2005; 43 Bennett (10.1016/S1473-3099(15)00536-8_bib19) 2012; 54 Mills (10.1016/S1473-3099(15)00536-8_bib20) 2006; 296 Rokx (10.1016/S1473-3099(15)00536-8_bib24) 2015; 60 Hoffmann (10.1016/S1473-3099(15)00536-8_bib14) 2009; 49 Tang (10.1016/S1473-3099(15)00536-8_bib26) 2012; 54 Garforth (10.1016/S1473-3099(15)00536-8_bib5) 2014; 6 Bulteel (10.1016/S1473-3099(15)00536-8_bib8) 2014; 68 Quinn (10.1016/S1473-3099(15)00536-8_bib29) 2000; 342 Chan (10.1016/S1473-3099(15)00536-8_bib30) 2012; 15 Sax (10.1016/S1473-3099(15)00536-8_bib12) 2009; 361 Apostolova (10.1016/S1473-3099(15)00536-8_bib18) 2015; 70 Gupta (10.1016/S1473-3099(15)00536-8_bib17) 2012; 380 Margot (10.1016/S1473-3099(15)00536-8_bib6) 2006; 7 Margot (10.1016/S1473-3099(15)00536-8_bib7) 2009; 52 Sunpath (10.1016/S1473-3099(15)00536-8_bib9) 2012; 26 31787204 - Lancet Infect Dis. 2018 Jan;18(1):21. doi: 10.1016/S1473-3099(17)30723-5. 27477976 - Lancet Infect Dis. 2016 Aug;16(8):890-1. doi: 10.1016/S1473-3099(16)30137-2. 26831126 - Lancet Infect Dis. 2016 May;16(5):512-513. doi: 10.1016/S1473-3099(16)00013-X. 27301917 - Lancet Infect Dis. 2016 Jun;16(6):636. doi: 10.1016/S1473-3099(16)30089-5. |
| References_xml | – volume: 49 start-page: 1928 year: 2009 end-page: 1935 ident: bib14 article-title: Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa publication-title: Clin Infect Dis – volume: 206 start-page: 1920 year: 2012 end-page: 1930 ident: bib22 article-title: HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status publication-title: J Infect Dis – volume: 26 start-page: 1679 year: 2012 end-page: 1684 ident: bib9 article-title: High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen publication-title: AIDS – volume: 208 start-page: 40 year: 2013 end-page: 49 ident: bib21 article-title: Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial publication-title: J Infect Dis – volume: 54 start-page: 862 year: 2012 end-page: 875 ident: bib26 article-title: A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy publication-title: Clin Infect Dis – volume: 342 start-page: 921 year: 2000 end-page: 929 ident: bib29 article-title: Viral load and heterosexual transmission of human immunodeficiency virus type 1 publication-title: N Engl J Med – volume: 9 start-page: 409 year: 2009 end-page: 417 ident: bib16 article-title: Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis publication-title: Lancet Infect Dis – volume: 54 start-page: S280 year: 2012 end-page: S289 ident: bib19 article-title: HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries publication-title: Clin Infect Dis – volume: 68 start-page: 77 year: 2014 end-page: 84 ident: bib8 article-title: The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort publication-title: J Infect – volume: 373 start-page: 48 year: 2009 end-page: 57 ident: bib3 article-title: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model publication-title: Lancet – volume: 22 start-page: 642 year: 2014 end-page: 650 ident: bib11 article-title: 2014 Update of the drug resistance mutations in HIV-1 publication-title: Top Antivir Med – volume: 61 start-page: 1453 year: 2015 end-page: 1461 ident: bib31 article-title: Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis publication-title: Clin Infect Dis – volume: 200 start-page: 1202 year: 2009 end-page: 1206 ident: bib32 article-title: Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C publication-title: J Infect Dis – volume: 201 start-page: 1303 year: 2010 end-page: 1307 ident: bib15 article-title: Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia publication-title: J Infect Dis – volume: 361 start-page: 2230 year: 2009 end-page: 2240 ident: bib12 article-title: Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy publication-title: N Engl J Med – volume: 8 start-page: e79981 year: 2013 ident: bib25 article-title: Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials publication-title: PLoS One – ident: bib2 article-title: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013 – volume: 15 start-page: 17701 year: 2012 ident: bib30 article-title: Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis publication-title: J Int AIDS Soc – year: 2014 ident: bib1 article-title: World AIDS Day 2014 Report - fact sheet – volume: 8 start-page: 50 year: 2013 end-page: 58 ident: bib4 article-title: The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review publication-title: Curr Opin HIV AIDS – volume: 7 start-page: 3703 year: 2015 end-page: 3718 ident: bib27 article-title: Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence publication-title: Viruses – volume: 70 start-page: 2693 year: 2015 end-page: 2708 ident: bib18 article-title: Efavirenz and the CNS: what we already know and questions that need to be answered publication-title: J Antimicrob Chemother – volume: 7 start-page: 442 year: 2006 end-page: 450 ident: bib6 article-title: Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 publication-title: HIV Med – volume: 296 start-page: 679 year: 2006 end-page: 690 ident: bib20 article-title: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis publication-title: JAMA – volume: 60 start-page: 143 year: 2015 end-page: 153 ident: bib24 article-title: Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort publication-title: Clin Infect Dis – volume: 52 start-page: 209 year: 2009 end-page: 221 ident: bib7 article-title: Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934 publication-title: J Acquir Immune Defic Syndr – volume: 15 start-page: 241 year: 2015 end-page: 247 ident: bib23 article-title: The future role of CD4 cell count for monitoring antiretroviral therapy publication-title: Lancet Infect Dis – volume: 6 start-page: 4080 year: 2014 end-page: 4094 ident: bib5 article-title: The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance publication-title: Viruses – volume: 191 start-page: 1403 year: 2005 end-page: 1409 ident: bib28 article-title: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda publication-title: J Infect Dis – volume: 27 start-page: 553 year: 2013 end-page: 561 ident: bib10 article-title: Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy publication-title: AIDS – volume: 43 start-page: 1395 year: 2005 end-page: 1400 ident: bib13 article-title: Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation publication-title: J Clin Microbiol – volume: 380 start-page: 1250 year: 2012 end-page: 1258 ident: bib17 article-title: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis publication-title: Lancet – volume: 361 start-page: 2230 year: 2009 ident: 10.1016/S1473-3099(15)00536-8_bib12 article-title: Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy publication-title: N Engl J Med doi: 10.1056/NEJMoa0906768 – volume: 8 start-page: e79981 year: 2013 ident: 10.1016/S1473-3099(15)00536-8_bib25 article-title: Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials publication-title: PLoS One doi: 10.1371/journal.pone.0079981 – volume: 6 start-page: 4080 year: 2014 ident: 10.1016/S1473-3099(15)00536-8_bib5 article-title: The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance publication-title: Viruses doi: 10.3390/v6104080 – volume: 8 start-page: 50 year: 2013 ident: 10.1016/S1473-3099(15)00536-8_bib4 article-title: The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e32835b809d – volume: 191 start-page: 1403 year: 2005 ident: 10.1016/S1473-3099(15)00536-8_bib28 article-title: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda publication-title: J Infect Dis doi: 10.1086/429411 – volume: 70 start-page: 2693 year: 2015 ident: 10.1016/S1473-3099(15)00536-8_bib18 article-title: Efavirenz and the CNS: what we already know and questions that need to be answered publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkv183 – volume: 296 start-page: 679 year: 2006 ident: 10.1016/S1473-3099(15)00536-8_bib20 article-title: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis publication-title: JAMA doi: 10.1001/jama.296.6.679 – volume: 7 start-page: 442 year: 2006 ident: 10.1016/S1473-3099(15)00536-8_bib6 article-title: Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 publication-title: HIV Med doi: 10.1111/j.1468-1293.2006.00404.x – volume: 206 start-page: 1920 year: 2012 ident: 10.1016/S1473-3099(15)00536-8_bib22 article-title: HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status publication-title: J Infect Dis doi: 10.1093/infdis/jis613 – volume: 200 start-page: 1202 year: 2009 ident: 10.1016/S1473-3099(15)00536-8_bib32 article-title: Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C publication-title: J Infect Dis doi: 10.1086/605894 – volume: 61 start-page: 1453 year: 2015 ident: 10.1016/S1473-3099(15)00536-8_bib31 article-title: Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis publication-title: Clin Infect Dis doi: 10.1093/cid/civ556 – volume: 7 start-page: 3703 year: 2015 ident: 10.1016/S1473-3099(15)00536-8_bib27 article-title: Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence publication-title: Viruses doi: 10.3390/v7072790 – volume: 54 start-page: 862 year: 2012 ident: 10.1016/S1473-3099(15)00536-8_bib26 article-title: A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy publication-title: Clin Infect Dis doi: 10.1093/cid/cir1034 – volume: 342 start-page: 921 year: 2000 ident: 10.1016/S1473-3099(15)00536-8_bib29 article-title: Viral load and heterosexual transmission of human immunodeficiency virus type 1 publication-title: N Engl J Med doi: 10.1056/NEJM200003303421303 – volume: 49 start-page: 1928 year: 2009 ident: 10.1016/S1473-3099(15)00536-8_bib14 article-title: Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa publication-title: Clin Infect Dis doi: 10.1086/648444 – volume: 22 start-page: 642 year: 2014 ident: 10.1016/S1473-3099(15)00536-8_bib11 article-title: 2014 Update of the drug resistance mutations in HIV-1 publication-title: Top Antivir Med – volume: 54 start-page: S280 issue: suppl 4 year: 2012 ident: 10.1016/S1473-3099(15)00536-8_bib19 article-title: HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries publication-title: Clin Infect Dis doi: 10.1093/cid/cis207 – volume: 52 start-page: 209 year: 2009 ident: 10.1016/S1473-3099(15)00536-8_bib7 article-title: Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181b05f7c – volume: 15 start-page: 241 year: 2015 ident: 10.1016/S1473-3099(15)00536-8_bib23 article-title: The future role of CD4 cell count for monitoring antiretroviral therapy publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70896-5 – volume: 43 start-page: 1395 year: 2005 ident: 10.1016/S1473-3099(15)00536-8_bib13 article-title: Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation publication-title: J Clin Microbiol doi: 10.1128/JCM.43.3.1395-1400.2005 – volume: 26 start-page: 1679 year: 2012 ident: 10.1016/S1473-3099(15)00536-8_bib9 article-title: High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen publication-title: AIDS doi: 10.1097/QAD.0b013e328356886d – volume: 27 start-page: 553 year: 2013 ident: 10.1016/S1473-3099(15)00536-8_bib10 article-title: Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy publication-title: AIDS doi: 10.1097/QAD.0b013e32835b0f59 – volume: 68 start-page: 77 year: 2014 ident: 10.1016/S1473-3099(15)00536-8_bib8 article-title: The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort publication-title: J Infect doi: 10.1016/j.jinf.2013.09.005 – volume: 15 start-page: 17701 year: 2012 ident: 10.1016/S1473-3099(15)00536-8_bib30 article-title: Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis publication-title: J Int AIDS Soc doi: 10.7448/IAS.15.2.17701 – volume: 201 start-page: 1303 year: 2010 ident: 10.1016/S1473-3099(15)00536-8_bib15 article-title: Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia publication-title: J Infect Dis doi: 10.1086/651618 – volume: 380 start-page: 1250 year: 2012 ident: 10.1016/S1473-3099(15)00536-8_bib17 article-title: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis publication-title: Lancet doi: 10.1016/S0140-6736(12)61038-1 – volume: 373 start-page: 48 year: 2009 ident: 10.1016/S1473-3099(15)00536-8_bib3 article-title: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model publication-title: Lancet doi: 10.1016/S0140-6736(08)61697-9 – volume: 9 start-page: 409 year: 2009 ident: 10.1016/S1473-3099(15)00536-8_bib16 article-title: Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(09)70136-7 – volume: 208 start-page: 40 year: 2013 ident: 10.1016/S1473-3099(15)00536-8_bib21 article-title: Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial publication-title: J Infect Dis doi: 10.1093/infdis/jis731 – volume: 60 start-page: 143 year: 2015 ident: 10.1016/S1473-3099(15)00536-8_bib24 article-title: Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort publication-title: Clin Infect Dis doi: 10.1093/cid/ciu763 – reference: 26831126 - Lancet Infect Dis. 2016 May;16(5):512-513. doi: 10.1016/S1473-3099(16)00013-X. – reference: 31787204 - Lancet Infect Dis. 2018 Jan;18(1):21. doi: 10.1016/S1473-3099(17)30723-5. – reference: 27477976 - Lancet Infect Dis. 2016 Aug;16(8):890-1. doi: 10.1016/S1473-3099(16)30137-2. – reference: 27301917 - Lancet Infect Dis. 2016 Jun;16(6):636. doi: 10.1016/S1473-3099(16)30089-5. |
| SSID | ssj0017104 |
| Score | 2.602659 |
| Snippet | Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent... Summary Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure... Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis... BACKGROUNDAntiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis... |
| SourceID | swepub pubmedcentral hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 565 |
| SubjectTerms | Africa South of the Sahara Alkynes Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral Therapy, Highly Active - adverse effects Benzoxazines - pharmacology Benzoxazines - therapeutic use Cyclopropanes Drug resistance Drug Resistance, Viral - drug effects Drug Resistance, Viral - genetics Emtricitabine Epidemiology Global Health HIV Infections - drug therapy HIV Infections - epidemiology HIV-1 - drug effects Human health and pathology Human immunodeficiency virus Human immunodeficiency virus 1 Humans Infectious Disease Infectious diseases Lamivudine - pharmacology Lamivudine - therapeutic use Life Sciences Mutation Pre-Exposure Prophylaxis - methods Prophylaxis Protease inhibitors Retrospective Studies Reverse Transcriptase Inhibitors - pharmacology Reverse Transcriptase Inhibitors - therapeutic use Risk factors Studies Tenofovir Viral Load - drug effects Viral Load - genetics |
| Title | Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1473309915005368 https://www.clinicalkey.es/playcontent/1-s2.0-S1473309915005368 https://dx.doi.org/10.1016/S1473-3099(15)00536-8 https://www.ncbi.nlm.nih.gov/pubmed/26831472 https://www.proquest.com/docview/1784468903 https://www.proquest.com/docview/1794495987 https://www.proquest.com/docview/1817848968 https://hal.science/hal-04985809 https://pubmed.ncbi.nlm.nih.gov/PMC4835583 http://kipublications.ki.se/Default.aspx?queryparsed=id:133372469 |
| Volume | 16 |
| WOSCitedRecordID | wos000374272900027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-4457 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 7X7 dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-4457 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 7RV dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (NC Live) customDbUrl: eissn: 1474-4457 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: BENPR dateStart: 20010801 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-4457 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017104 issn: 1473-3099 databaseCode: 8C1 dateStart: 20010801 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbhMxELVoixAS4lJugVIZhBA8mK53vWubF1SqVkGCUBUoebP2YtMIuluySSW-hl9lxnuJokKLxIsVeT2J7cyOz9jjOYQ8DWHm8yhzDIyjZiLnnKk8EszGymYu1i7OU082IUcjNR7r_XbDrW7DKjub6A11UeW4R77FpQLPRekgen3ygyFrFJ6uthQaK2SNIzYGfZYHh_0pAqye_lRZyIhFAIUWN3i2PvaVz3n8AlUxYepva9PKEQZJnkWgZwMpl9KN-iVq78b_Du4mud6CU7rdaNMtcsmW6-TK-_b4fZ1cazb5aHN36Tb51TAGULugmf1JK0eL6fwrBT8esSkoFfVE5NSlE4yBxwZfhh8ouuLHx34HnroJgFCGiJciUwTU1hTQNPXZQejw7SHjtAsbK1_RlPo4SD8fKDGbVt2NUYqMv9MZ9Wlz75DPe7ufdoasZXxguZTxjKk4LIQrZJyCmyZknihQFV4A5BKZFk660IZBaJPUWpsHDqlSisjxQmZaFpgb8C5ZLavS3ic0tQFYq0BIYTMRFFanRZhqkE-iKFaZGxDR_dcmb9OhIyvHd9PHvaGKGFQRw2PjVcSoAXnZi500-UAuEkg6RTLdZVcwzwZWrIsE5Z8Ebd0amdpwU4cmaKRRGLA9ioKk6iVbHNXgo3_50Seg6_3IMPf4cPudwTpwJVWsAn3KB2Sj02Kz6EyvwgPyuH8MtgoPoNLSVnNsowU45FrJc9oo_CalcRj3mrer706YqAh6HcLULL13S_1dflJOjnzOdKGQRwD69qx5Q5dE2qpv8MkacJBgFXtw_hgfkquAnJMm8nWDrM6mc_uIXM5PZ5N6uumtEJZj6UsFpdrhm2Ttze5o_-A37VyQzQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ZbxMxELbaggAJcZQrUMAgQPBguod3bSMhVAFVoqalEgXyZvawaQRNym5S1F_DP-A3MuM9oqjQ8tIH3iKvv43tndMezxDyKICVz8LUMhCOivHM95nMQs5MJE1qI2WjLHHFJsTWlhwM1PYC-dXchcGwykYmOkGdjzPcI1_1hQTPRSovfLX_nWHVKDxdbUpoVGSxYQ5_gMtWvuy9ge_7OAjW3-687rK6qgDLhIgmTEZBzm0uogRcAS6yWMJw_BzUOk8Vt8IGJvACEyfGmMyzWI4jD62fi1SJHPPPwXsXyRmQ4wKdPTFoHTwftLU7xeYiZCGYXrMbQ6vv28anfvQMST9m8m-6cHEXgzKPWrxHAzfn0ps6lbh--X9bzCvkUm1807WKW66SBTNaJuc26_CCZXKx2sSk1d2sa-RnVRGBmlkZ3UM6tjQvpl9oYUq0vYFpqCu0Tm0yxBh_7PCp-47iVsPenjthoHYIRjZDi55iJQxoLSl4C9RlP6Hd3kfm0yYsbvSCJtTFebr1R8SkGDc3YilWNC4m1KUFvk4-nMpy3SBLo_HI3CI0MR5IY48LblLu5UYleZAowMdhGMnUdghvaEtndbp3rDryTbdxfUiSGklS-5F2JKllhzxvYftVvpOTAHFDuLq5zAvqR4NGPgko_gQ0ZS1ES-3rMtBehUYw-C4IBaRskbWdWNl___KnD4G32plhbvXuWl9jG7jKMpKeOvA7ZKXhGj0bTMsyHfKgfQyyGA_YkpEZT7GP4lxFSopj-kh8k1Q4jZsVN7fDCWIZwqgDWJo5Pp8b7_yT0XDX5YTnEuskwNieVBJhDlI3fYVfRoMDCFr69vFzvE_Od3c2-7rf29q4Qy6AlxBXUb4rZGlSTM1dcjY7mAzL4p6TgJR8Pm0p8Ru7L-k4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ZbxMxELbagiokxFGuQAGDAMGDyR7etY2EUNVSJWoJlbj6ZvawaQRNym5S1F_D_-DXMeM9oqjQ8tIH3iKvZzP2ei57PB8hjwKY-SxMLQPlqBjPfJ_JLOTMRNKkNlI2yhIHNiEGA7m7q3YWyK_mLgymVTY60SnqfJzhHnnXFxIiF6m8sGvrtIidjc1XB98ZIkjhSWsDp1EtkS1z9APCt_JlfwO-9eMg2Hz9fr3HaoQBlgkRTZiMgpzbXEQJhAVcZLEE1vwcTDxPFbfCBibwAhMnxpjMswjNkYfWz0WqRI616OC9i-ScCOMQAz-53qaX-GC53Yk2FyELwQ2b3R7qvmsbn_rRMxSDmMm_2cXFPUzQPO79Hk_inCt16szj5uX_eWKvkEu1U07XKim6ShbMaIUsv6nTDlbIxWpzk1Z3tq6RnxVSAjUzeN0jOrY0L6ZfaGFK9MlBmKgDYKc2GWLuP3b41HtLcQtif9-dPFA7BOeboadPESEDWksKUQR1VVFor_-R-bRJlxu9oAl1-Z_uWyDFpBg3N2UpIh0XE-rKBV8nH85kum6QpdF4ZG4RmhgPtLTHBTcp93KjkjxIFNDHYRjJ1HYIb9aZzuoy8IhG8k23-X64PDUuT-1H2i1PLTvkeUt2UNVBOY0gbhaxbi75glnSYKlPIxR_IjRlrVxL7esy0F5FjcQQ0yApUMqWsvYfK7_wX_70IchZOzKsud5b29bYBiG0jKSnDv0OWW0kSM-YacWnQx60j0FH48FbMjLjKfZRnKtISXFCH4lvkgqHcbOS7JadIJYhcB3A1MzJ_By_809Gwz1XK55LxE8A3p5U2mGOpG76Cr-MhsAQrPftk8d4nyyDctDb_cHWHXIBgoe4Sv5dJUuTYmrukvPZ4WRYFvecMqTk81krid-6U_G_ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Global+epidemiology+of+drug+resistance+after+failure+of+WHO+recommended+first-line+regimens+for+adult+HIV-1+infection%3A+a+multicentre+retrospective+cohort+study&rft.jtitle=The+Lancet+infectious+diseases&rft.date=2016-05-01&rft.eissn=1474-4457&rft.volume=16&rft.issue=5&rft.spage=565&rft.epage=575&rft_id=info:doi/10.1016%2FS1473-3099%2815%2900536-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-3099&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-3099&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-3099&client=summon |